La Jolla Pharmaceutical Co. (LJPC) was a big mover last session with its shares rising over 12% on the day. The upside was owing to the company’s announcement that Lakhmir S. Chawla, M.D. and Chief Medical Officer, recently received the International Vicenza Award for Critical Care Nephrology at the 33rd Course on Critical Care Nephrology. This development led to far more shares changing hands yesterday than in a normal session. The move continues the recent uptrend of the company as the stock has gained roughly 22% since June 19.
This biopharmaceutical company has seen no estimate revision in the last 30 days. The Zacks Consensus Estimate hasn’t been in trend either. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.
La Jolla Pharmaceutical currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
Another stock worth considering in the Med-Drugs industry is Portola Pharmaceuticals, Inc. (PTLA) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment